NCT06816771View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Rhabdomyosarcoma, Recurrent, Refractory
Interventions
DRUG

pazopanib

Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.

DRUG

TGI chemotherapy

TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)

DRUG

CIV chemotherapy

CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)

Trial Locations (1)

China,250117

RECRUITING

No. 440 Jiyan Road, Jinan City, Shandong Province, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER